Effect of haemodialysis on the pharmacokinetics of cetirizine.
The pharmacokinetics of Cetirizine, a histamine H1-receptor antagonist, were investigated in five renal failure patients undergoing chronic haemodialysis therapy. The patients received one 10 mg cetirizine dihydrochloride capsule 3 h before haemodialysis. Concentrations of cetirizine in serum and dialysate were determined by HPLC. The maximum serum cetirizine concentration and the time to reach that maximum were 285 micrograms.l-1 and 2.0 h, respectively. The terminal disposition half-life of cetirizine in these patients was 19.3 h. The haemodialysis clearance of cetirizine was 14.0 ml. min-1. Although this is approximately 33% of the apparent total body clearance of cetirizine in subjects with normal renal function, the fraction of the dose removed by dialysis was only 9.4%. Thus, since haemodialysis does not produce a clinically significantly alteration in cetirizine elimination, no supplemental dose should be necessary after dialysis.
Awni
W M
WM
Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota.
Yeh
J
J
Halstenson
C E
CE
Opsahl
J A
JA
Chung
M
M
Matzke
G R
GR
D000328:Adult; D000368:Aged; D017332:Cetirizine; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006207:Half-Life; D006634:Histamine H1 Antagonists / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D006919:Hydroxyzine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors
D006634:Histamine H1 Antagonists; D006919:Hydroxyzine; D017332:Cetirizine